Literature DB >> 2680867

Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability.

P M Grambsch1, E R Dickson, M Kaplan, G LeSage, T R Fleming, A L Langworthy.   

Abstract

The generalizability of the Mayo model for predicting survival in individual primary biliary cirrhosis patients without liver transplantation was tested and confirmed. The model was applied to a data base of patients from the New England Medical Center Hospitals (n = 141) and the Scott and White Clinic (n = 35) and found to predict their survival accurately. It was also shown to be accurate for Mayo primary biliary cirrhosis patients with very advanced disease (n = 30), those with less than a 33% chance of surviving 12 months. The analyses confirmed that the addition of histologic stage did not significantly improve the predictive power of the model (p greater than 0.10). We suggest that the Mayo model is a practical tool for clinical management and decision making.

Entities:  

Mesh:

Year:  1989        PMID: 2680867     DOI: 10.1002/hep.1840100516

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 2.  Parenchymal liver disease in the elderly.

Authors:  O F James
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

3.  Hepatic ADC map as an adjunct to conventional abdominal MRI to evaluate hepatic fibrotic and clinical cirrhotic severity in biliary atresia patients.

Authors:  Steven Shinn-Forng Peng; Yung-Ming Jeng; Wen-Ming Hsu; Justin Cheng-Ta Yang; Ming-Chih Ho
Journal:  Eur Radiol       Date:  2015-04-29       Impact factor: 5.315

4.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

5.  Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI.

Authors:  Henrik Nilsson; Lennart Blomqvist; Lena Douglas; Anders Nordell; Eduard Jonas
Journal:  HPB (Oxford)       Date:  2010-10       Impact factor: 3.647

6.  Current advances in liver transplantation.

Authors:  J D Eason; D L Rowell
Journal:  Ochsner J       Date:  1999-01

Review 7.  Clinical features and management of primary biliary cirrhosis.

Authors:  Andrea Crosignani; Pier-Maria Battezzati; Pietro Invernizzi; Carlo Selmi; Elena Prina; Mauro Podda
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

8.  Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.

Authors:  M Longo; A Crosignani; P M Battezzati; C Squarcia Giussani; P Invernizzi; M Zuin; M Podda
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 9.  The unfinished business of primary biliary cirrhosis.

Authors:  Carlo Selmi; Massimo Zuin; M Eric Gershwin
Journal:  J Hepatol       Date:  2008-07-02       Impact factor: 25.083

10.  Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Authors:  Phunchai Charatcharoenwitthaya; Jayant A Talwalkar; Paul Angulo; Andrea A Gossard; Jill C Keach; Janice L Petz; Roberta A Jorgensen; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2009-03-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.